Acromegaly is a relatively rare chronic disease. Nevertheless, it is life-threatening in its sequelae, for example, hypertension and cardiovascular disease. Since it also has disfiguring properties - especially of the head and face - acromegaly has serious psychological consequences which are reinforced by the awareness of factors such as excessive sweating. It is precisely on these signs and symptoms that Sandostatin R has a rapid effect, thus improving the patient's quality of life as well as counteracting the underlying processes. SandostatinÊ

1. Clinical Aspects of Growth Hormone Hypersecretory States

2. Correlation Between Preoperative Testing and Tumour Morphology in Acromegaly
3. Acromegaly: Objectives of Therapy
4. Surgical Treatment of Acromegaly
5. External Radiation Therapy of Acromegaly
6. Bromocriptine Treatment of Acromegaly
7. Chemical Structure, Pharmacodynamic Profile and Pharmacokinetics of SMS 201-995 (Sandostatin®)
8. Studies on the Acute and Chronic Effects of Sandostatin® in Acromegaly
9. Medical Treatment of Acromegaly. Dopaminergic Agonists and Long-Acting Somatostatin
10. Treatment of Acromegaly with the Somatostatin Analogue SMS 201-995 (Sandostatin®)
11. Observations During a Clinical Trial of Sandostatin® in Acromegalic Patients
12. Effects of Long-Term Administration of Sandostatin® (SMS 201-995) at Increasing Doses in 40 Acromegalic Patients. Results from the French Sandostatin Acromegaly Study Group
13. Experience with Sandostatin® in Various Groups of Acromegalic Patients
14. Treatment of Acromegaly with SMS 201-995 (Sandostatin®): Clinical, Biochemical and Morphologic Study
15. Long-Term Treatment of Acromegaly by Continuous Subcutaneous Infusion of the Long-Acting Somatostatin Analog Sandostatin® (SMS 201-995, Octreotide)
16. Sandostatin® (SMS 201-995) Treatment of Acromegaly: Acute and Chronic Effects
17. Long-Term Efficacy of Sandostatin® (SMS 201-995, Octreotide) in 178 Acromegalic Patients. Results from the International Multicentre Acromegaly Study Group
18a. Pulsatile Administration of SMS 201-995 (Sandostatin®) in the Treatment of Acromegaly
18b. Treatment of Acromegaly with SMS 201-995 (Sandostatin®): A Collaborative Study in Japan
19. Long-Term Treatment of Resistant Acromegaly with a Somatostatin Analog (SMS 201-995,Sandostatin®)
20. High-Dose, Long-Term, Continuous Subcutaneous Infusion of SMS 201-995 (Sandostatin®) in Acromegaly
21. Long-Term Therapy of Acromegaly with SMS 201-995 (Sandostatin®)
22. Successful Treatment of Ophthalmoplegia in Acromegaly with the Somatostatin Analogue SMS 201-995 (Sandostatin®)
23. Sandostatin® (SMS 201-995) in the Treatment of Acromegaly
24. Somatostatin Octapeptide (SMS 201-995, Sandostatin®) in the Medical Treatment of Acromegaly
25a. SMS 201-995 (Sandostatin®) Treatment of Therapy-Resistant Acromegaly
25b. Sandostatin® (SMS 201-995) Can Exert a Direct Analgesic Effect
25c. Relapsing Acromegaly Resistant to Both Bromocriptine and Sandostatin® Treatment
26. Consensus Discussion and Conclusions.